BC Innovations | Aug 8, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Adrenergic receptor b2 (ADRB2); ADRB3; muscarinic acetylcholine receptor M1 (CHRM1; HM1) Mouse studies suggest inhibiting autonomic nerve development in the tumor microenvironment could...
BC Week In Review | Jun 10, 2013
Clinical News

RHB-101 regulatory update

RedHill said it plans to submit an NDA to FDA and an MAA to EMA no earlier than 2H14 for RHB-101 to treat congestive heart failure and hypertension after it met with FDA to discuss...
BC Week In Review | Mar 25, 2013
Clinical News

Carvedilol regulatory update

RedHill said it plans to submit an MAA for RHB-101 to treat hypertension under the EU's Mutual Recognition Procedure, with Denmark acting as the reference member state. RedHill said it is "continuing to explore the...
BC Innovations | Jul 21, 2011
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Arrhythmia Store overload-induced Ca2 release (SOICR) In vitro and mouse studies suggest SOICR inhibitors could increase the efficacy of b-blockers to prevent ventricular arrhythmia....
BC Innovations | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

Researchers at The Scripps Research Institute have used a cell-based model of HCV infection to identify compounds on the market or in development for other indications that could be repurposed to treat HCV. 1 But...
BC Week In Review | Mar 30, 2009
Company News

Flamel, GlaxoSmithKline deal

Flamel will receive a $4 million milestone from GlaxoSmithKline under a 2004 deal for Flamel to manufacture the pharma's Coreg CR , a controlled-release formulation of the beta blocker Coreg carvedilol to treat heart failure. The...
BC Week In Review | Feb 9, 2009
Clinical News

Coreg CR and ACE inhibitor: Development discontinued

GSK terminated development of a fixed-dose combination of Coreg CR and an undisclosed angiotensin-converting enzyme (ACE) inhibitor, which was in Phase III testing to treat hypertension. Coreg CR, which uses Micropump technology from Flamel, is...
BioCentury | Feb 9, 2009

Ebb & Flow

Novartis (NYSE:NVS; SWX:NOVN) caused some stir last week when it unveiled plans for a $5 billion bond issue that the company said will be used "for general corporate purposes outside of Switzerland." With Pfizer (NYSE:PFE)...
BC Extra | Feb 6, 2009
Company News

GSK expands restructuring, reports earnings

GlaxoSmithKline (LSE:GSK; NYSE:GSK) said in its 4Q08 earnings that it will expand the restructuring program that the company began in 2007. GSK said it will cut its U.S. primary care sales force by 1,800 and...
BioCentury | Sep 29, 2008
Product Development

BEST foot forward

FDA last week accepted for filing an NDA for Arca biopharma Inc. 's beta blocker, Gencaro bucindolol. But the company has an interesting circle to square. It is hoping the agency approves bucindolol to treat...
Items per page:
1 - 10 of 65